IN2014CN00961A - - Google Patents
Info
- Publication number
- IN2014CN00961A IN2014CN00961A IN961CHN2014A IN2014CN00961A IN 2014CN00961 A IN2014CN00961 A IN 2014CN00961A IN 961CHN2014 A IN961CHN2014 A IN 961CHN2014A IN 2014CN00961 A IN2014CN00961 A IN 2014CN00961A
- Authority
- IN
- India
- Prior art keywords
- compounds
- intended
- lsd1
- methods
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161523801P | 2011-08-15 | 2011-08-15 | |
| PCT/US2012/050948 WO2013025805A1 (fr) | 2011-08-15 | 2012-08-15 | Analogues de (e)-n'-(1-phényléthylidène)benzohydrazide substitués en tant qu'inhibiteurs de l'histone déméthylase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN00961A true IN2014CN00961A (fr) | 2015-04-10 |
Family
ID=47715455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN961CHN2014 IN2014CN00961A (fr) | 2011-08-15 | 2012-08-15 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US8987335B2 (fr) |
| EP (1) | EP2744330B1 (fr) |
| JP (1) | JP6122006B2 (fr) |
| KR (1) | KR101983537B1 (fr) |
| CN (1) | CN103929960B (fr) |
| AU (1) | AU2012296639B2 (fr) |
| BR (1) | BR112014003382B1 (fr) |
| CA (1) | CA2843609C (fr) |
| CY (1) | CY1123345T1 (fr) |
| DK (1) | DK2744330T3 (fr) |
| EA (1) | EA026389B1 (fr) |
| ES (1) | ES2821548T3 (fr) |
| HK (1) | HK1200052A1 (fr) |
| HR (1) | HRP20201433T1 (fr) |
| HU (1) | HUE050962T2 (fr) |
| IL (1) | IL230728A (fr) |
| IN (1) | IN2014CN00961A (fr) |
| LT (1) | LT2744330T (fr) |
| MX (1) | MX356486B (fr) |
| PL (1) | PL2744330T3 (fr) |
| PT (1) | PT2744330T (fr) |
| SG (1) | SG2014009609A (fr) |
| SI (1) | SI2744330T1 (fr) |
| WO (1) | WO2013025805A1 (fr) |
| ZA (1) | ZA201400881B (fr) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9266838B2 (en) | 2011-08-15 | 2016-02-23 | University Of Utah Research Foundation | Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors |
| CA2885969C (fr) | 2012-10-02 | 2021-04-06 | Epitherapeutics Aps | Derives de pyridine substitues et leurs compositions utiles comme inhibiteurs d'histone demethylases |
| US9650339B2 (en) * | 2013-02-27 | 2017-05-16 | Gilead Sciences, Inc. | Inhibitors of histone demethylases |
| US9738637B2 (en) * | 2013-03-12 | 2017-08-22 | Celgene Quantical Research, Inc. | Histone demethylase inhibitors |
| SG10201710543PA (en) * | 2013-06-19 | 2018-02-27 | Univ Utah Res Found | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors |
| ES2901711T3 (es) | 2014-02-13 | 2022-03-23 | Incyte Corp | Ciclopropilaminas como inhibidores de LSD1 |
| ME03580B (fr) | 2014-02-13 | 2020-07-20 | Incyte Corp | Cyclopropylamines en tant qu'inhibiteurs de lsd1 |
| EP3105219B9 (fr) | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamines en tant qu'inhibiteurs de lsd1 |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| WO2015153516A1 (fr) * | 2014-04-04 | 2015-10-08 | University Of Florida Research Foundation | Composés inhibiteurs de hdac et méthodes de traitement |
| WO2015188130A1 (fr) * | 2014-06-05 | 2015-12-10 | The University Of Kansas | Analogues du marmelin et méthodes d'utilisation dans le traitement du cancer |
| WO2016007722A1 (fr) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1 |
| WO2016007731A1 (fr) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines et imidazopyrazines à utiliser en tant qu'inhibiteurs de lsd1 |
| WO2016007727A1 (fr) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1 |
| US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
| BR112017003442A2 (pt) | 2014-08-27 | 2017-11-28 | Gilead Sciences Inc | compostos e métodos para inibir histona desmetilases |
| EP2993175A1 (fr) | 2014-09-05 | 2016-03-09 | IEO - Istituto Europeo di Oncologia Srl | Thiénopyrroles en tant qu'inhibiteurs de l'histone déméthylase |
| CN106146361A (zh) * | 2015-03-16 | 2016-11-23 | 四川大学 | 茚-1-亚基磺酰基苯甲酰肼衍生物及其制备方法和用途 |
| SG11201708047UA (en) | 2015-04-03 | 2017-10-30 | Incyte Corp | Heterocyclic compounds as lsd1 inhibitors |
| AU2016275702A1 (en) | 2015-06-12 | 2017-12-21 | Oryzon Genomics, S.A. | Biomarkers associated with LSD1 inhibitors and uses thereof |
| WO2017013061A1 (fr) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarqueurs associés à des inhibiteurs de lsd1 et utilisations de ceux-ci |
| MY189367A (en) | 2015-08-12 | 2022-02-08 | Incyte Corp | Salts of an lsd1 inhibitor |
| CN109195593A (zh) | 2016-03-15 | 2019-01-11 | 奥莱松基因组股份有限公司 | 用于治疗实体瘤的lsd1抑制剂的组合 |
| WO2017158136A1 (fr) | 2016-03-16 | 2017-09-21 | Oryzon Genomics, S.A. | Procédés de détermination de l'engagement d'une cible kdm1a et chimiosondes utiles correspondantes |
| AR109452A1 (es) | 2016-04-22 | 2018-12-12 | Incyte Corp | Formulación farmacéutica de un inhibidor de lsd1 y método de tratamiento |
| EP3246330A1 (fr) | 2016-05-18 | 2017-11-22 | Istituto Europeo di Oncologia S.r.l. | Imidazoles comme inhibiteurs de histone demethylase |
| US11427543B2 (en) | 2016-07-19 | 2022-08-30 | The General Hospital Corporation | Compounds for targeting cancer stem cells |
| WO2018083189A1 (fr) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Biomarqueurs pour déterminer la sensibilité à des inhibiteurs de lsd1 |
| EP3535414A1 (fr) | 2016-11-03 | 2019-09-11 | Oryzon Genomics, S.A. | Biomarqueurs pharmacodynamiques pour traitement du cancer personnalisé à l'aide d'agents de modification épigénétique |
| MA51507A (fr) | 2016-12-09 | 2020-11-11 | Constellation Pharmaceuticals Inc | Marqueurs pour un traitement personnalisé du cancer avec des inhibiteurs de lsd1 |
| CN106831489B (zh) * | 2017-03-23 | 2018-04-17 | 郑州大学 | 苯环丙胺酰腙类化合物、制备方法及其应用 |
| SG11202000077RA (en) | 2017-08-03 | 2020-02-27 | Oryzon Genomics Sa | Methods of treating behavior alterations |
| US10980777B2 (en) | 2017-08-18 | 2021-04-20 | Istituto Europeo Di Oncologia S.R.L. | Indole derivatives as histone demethylase inhibitors |
| WO2019068326A1 (fr) | 2017-10-05 | 2019-04-11 | Université D'aix-Marseille | Inhibiteurs de la lsd1 pour le traitement et la prévention de cardiomyopathies |
| UA128288C2 (uk) | 2018-03-08 | 2024-05-29 | Інсайт Корпорейшн | СПОЛУКИ АМІНОПІРАЗИНДІОЛУ ЯК ІНГІБІТОРИ PI3K-<font face="Symbol">g</font> |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| WO2020047198A1 (fr) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Sels d'un inhibiteur de lsd1 et leurs procédés de préparation |
| CN109793742A (zh) * | 2019-03-04 | 2019-05-24 | 四川大学华西医院 | 一种药物化合物应用 |
| CN109758442B (zh) * | 2019-03-20 | 2021-08-17 | 武汉大学 | 二芳基酰肼类化合物在制备抗流感病毒药物中的应用 |
| AU2020242302A1 (en) | 2019-03-20 | 2021-09-16 | Oryzon Genomics, S.A. | Methods of treating borderline personality disorder |
| WO2020188089A1 (fr) | 2019-03-20 | 2020-09-24 | Oryzon Genomics, S.A. | Procédés de traitement d'un trouble d'hyperactivité avec déficit de l'attention au moyen d'inhibiteurs de kdm1a tels que le composé vafidemstat |
| EP3994280A1 (fr) | 2019-07-05 | 2022-05-11 | Oryzon Genomics, S.A. | Biomarqueurs et procédés pour le traitement personnalisé d'un cancer du poumon à petites cellules au moyen d'inhibiteurs de kdm1a |
| US20220047528A1 (en) * | 2020-07-24 | 2022-02-17 | Salarius Pharmaceuticals Llc | Methods of inhibiting lysine-specific demethylase 1 (lsd-1) |
| EP3964204A1 (fr) | 2020-09-08 | 2022-03-09 | Université d'Aix-Marseille | Composés destinés à être utilisés dans le traitement et la prévention de la fibrose de tissus |
| MX2023011779A (es) | 2021-04-08 | 2023-11-22 | Oryzon Genomics Sa | Combinaciones de inhibidores de lsd1 para el tratamiento de canceres mieloides. |
| WO2023217758A1 (fr) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Méthodes de traitement d'une tumeur maligne des gaines des nerfs périphériques (tmgnp) à l'aide d'inhibiteurs de lsd1 |
| WO2023217784A1 (fr) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Méthodes de traitement de tumeurs mutantes nf1 à l'aide d'inhibiteurs de lsd1 |
| WO2024110649A1 (fr) | 2022-11-24 | 2024-05-30 | Oryzon Genomics, S.A. | Combinaisons d'inhibiteurs de lsd1 et d'inhibiteurs de ménine pour le traitement du cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040110963A1 (en) * | 2001-01-22 | 2004-06-10 | Kaspar Burri | Novel hydrazones |
| JP2002302472A (ja) * | 2001-01-31 | 2002-10-18 | Meiji Seika Kaisha Ltd | メイラード反応阻害剤 |
| JPWO2005007151A1 (ja) | 2003-07-16 | 2006-08-31 | 株式会社医薬分子設計研究所 | 皮膚色素沈着の治療剤 |
| WO2006136008A1 (fr) | 2005-05-24 | 2006-12-28 | University Health Network | Hydrazones d'acide salicylique comme inhibiteurs de voie d'erk/ map kinase et pour le traitement du cancer |
| TW200800145A (en) | 2005-08-26 | 2008-01-01 | Dekk Tec Inc | Hydrazone agents to treat cutaneous lesions |
| CN101541348A (zh) | 2005-11-03 | 2009-09-23 | 红点生物公司 | 腙衍生物及其用途 |
| US8338464B2 (en) | 2006-11-30 | 2012-12-25 | Albert Einstein College Of Medicine Of Yeshiva University | Small molecule inhibitors of BCL6 |
| EP2107908A4 (fr) | 2007-02-02 | 2011-07-20 | Redpoint Bio Corp | Utilisation d'un inhibiteur de trpm5 pour réguler une sécrétion d'insuline et de glp-1 |
| BRPI0809498A2 (pt) * | 2007-04-02 | 2014-09-23 | Inst Oneworld Health | Compostos inibidores de cftr e seus usos |
| WO2009027349A2 (fr) * | 2007-08-24 | 2009-03-05 | Oryzon Genomics Sa | Traitement et prévention de maladies neurodégénératives |
| AR070898A1 (es) * | 2008-03-18 | 2010-05-12 | Solvay Pharm Bv | Derivados de arilsulfonil pirazolin carboxamidina como antagonistas de 5-ht6 |
| JP2011526925A (ja) | 2008-07-01 | 2011-10-20 | ザカロン ファーマシューティカルズ，インク． | ヘパラン硫酸阻害剤 |
| EP2376440A2 (fr) * | 2009-01-14 | 2011-10-19 | Dow AgroSciences LLC | Compositions fongicides à base de dérivés d'hydrazone et de cuivre |
| CA2727890A1 (fr) | 2010-01-13 | 2011-07-13 | Norbert Kartner | Composes, compositions et traitements destines a des maladies mettant en cause des atpases de type v |
-
2012
- 2012-08-15 WO PCT/US2012/050948 patent/WO2013025805A1/fr active Application Filing
- 2012-08-15 BR BR112014003382-0A patent/BR112014003382B1/pt active IP Right Grant
- 2012-08-15 PT PT128235405T patent/PT2744330T/pt unknown
- 2012-08-15 PL PL12823540T patent/PL2744330T3/pl unknown
- 2012-08-15 SG SG2014009609A patent/SG2014009609A/en unknown
- 2012-08-15 DK DK12823540.5T patent/DK2744330T3/da active
- 2012-08-15 HU HUE12823540A patent/HUE050962T2/hu unknown
- 2012-08-15 EP EP12823540.5A patent/EP2744330B1/fr active Active
- 2012-08-15 CN CN201280050736.9A patent/CN103929960B/zh active Active
- 2012-08-15 US US13/586,603 patent/US8987335B2/en active Active
- 2012-08-15 SI SI201231841T patent/SI2744330T1/sl unknown
- 2012-08-15 KR KR1020147006969A patent/KR101983537B1/ko active IP Right Grant
- 2012-08-15 EA EA201490453A patent/EA026389B1/ru unknown
- 2012-08-15 AU AU2012296639A patent/AU2012296639B2/en active Active
- 2012-08-15 MX MX2014001842A patent/MX356486B/es active IP Right Grant
- 2012-08-15 LT LTEP12823540.5T patent/LT2744330T/lt unknown
- 2012-08-15 JP JP2014526170A patent/JP6122006B2/ja active Active
- 2012-08-15 ES ES12823540T patent/ES2821548T3/es active Active
- 2012-08-15 CA CA2843609A patent/CA2843609C/fr active Active
- 2012-08-15 IN IN961CHN2014 patent/IN2014CN00961A/en unknown
-
2014
- 2014-01-30 IL IL230728A patent/IL230728A/en active IP Right Grant
- 2014-02-05 ZA ZA2014/00881A patent/ZA201400881B/en unknown
-
2015
- 2015-01-15 HK HK15100490.8A patent/HK1200052A1/xx unknown
- 2015-02-16 US US14/623,370 patent/US9555024B2/en active Active
-
2020
- 2020-09-08 HR HRP20201433TT patent/HRP20201433T1/hr unknown
- 2020-09-14 CY CY20201100866T patent/CY1123345T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN00961A (fr) | ||
| WO2014194280A3 (fr) | Nouveaux inhibiteurs suicides de la lsd1 ciblant les cellules cancéreuses exprimant le sox2 | |
| CY1122556T1 (el) | Υποκατεστημενα αναλογα ν-φαινυλπυριμιδιν-2- αμινης ως αναστολεις της κινασης axl | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| EA201890086A1 (ru) | 1,4-замещенные производные пиперидина | |
| EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
| WO2012118563A3 (fr) | Analogues de 6-alkyl-n-(pyridin-2-yl)-4-aryloxypicolinamide en tant que modulateurs allostériques négatifs de mglur5 et procédé pour les préparer et les utiliser | |
| EA201691428A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
| WO2014055934A3 (fr) | Analogues de n-(3-(pyrimidin-4-yl)phényl) substitué utilisés en tant qu'inhibiteurs de récepteur tyrosine kinase btk | |
| WO2014055928A3 (fr) | Analogues de n-(3-(pyrimidin-4-yl)phényl) substitué utilisés en tant qu'inhibiteurs de récepteur tyrosine kinase btk | |
| CL2016003301A1 (es) | Compuestos derivados del ácido amino-(piridin-4-carboxílico) sustituidos, inhibidores de la histona desmetilasa; composición farmacéutica, que los comprende, útiles en el tratamiento del cáncer, tales como el cáncer de próstata, mama, vejiga, pulmón y/o melanoma. | |
| AR084433A1 (es) | Inhibidores de la faah y composiciones farmaceuticas que los contienen | |
| EA201391230A1 (ru) | Соединения и композиции в качестве ингибиторов trk | |
| CA2818187C (fr) | Inhibiteurs de bromodomaines et leurs utilisations | |
| MX355907B (es) | Pirrolopirazina-piperidina espirociclica-amidas como moduladores de canales de ionicos. | |
| WO2013170072A3 (fr) | Composés pour le traitement de troubles neurologiques | |
| MX350862B (es) | Acidos de piperidinil naftilacetico. | |
| PH12014502586A1 (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| ECSP14030538A (es) | Inhibidores de dgat1 de éter cíclico de cabeza de puente | |
| PE20150224A1 (es) | Inhibidores del nampt | |
| EA201490152A1 (ru) | Антагонисты trpm8 и их применение при лечении | |
| EP2575461A4 (fr) | 6-méthylnicotinamides substitués utiles en tant que modulateurs allostériques positifs de mglur5 | |
| MD20160105A2 (ro) | 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide | |
| WO2013006734A8 (fr) | Analogues de 4-phénoxyphénol substitués en tant que modulateurs de l'activité de l'antigène nucléaire de prolifération cellulaire | |
| PH12015500795B1 (en) | N-(2-(cyclic amine)ethyl)benzamide derivatives as p2x7 inhibitors |